{"createdAt":"8/2/2020, 2:10:13 PM","timestamp":1596391813439,"Company ID number":"372","DMX_ISSUER_NAME":"HUADONG MEDICINE CO .,LTD","DMX_ISSUER_ID":"IID000000002169670","Country of Classification":"CHINA","name":"Huadong Medicine Co Ltd ","code":"000963","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"华东医药股份有限公司_吕梁","group":"board","name":"吕梁","title":"董事长,董事","isMale":true,"age":"46","degree":"硕士","salary":"200.0万","stockAmount":"-","description":"吕梁,男,1974年出生,中欧国际工商学院工商管理硕士。1997年7月至2001年7月,任远大资产管理有限公司项目经理;2001年7月至2010年3月,就职于常熟雷允上制药有限公司,历任副总经理、总经理;2010年4月至2016年1月担任华东医药股份有限公司董事、副总经理;2016年1月至今任华东医药股份有限公司董事、总经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_李邦良","group":"board","name":"李邦良","title":"名誉董事长","isMale":true,"age":"74","degree":"本科","salary":"220.0万","stockAmount":"-","description":"李邦良,男,1946年出生,大学本科,教授级高工。1972年至今在公司工作,历任:技术员、车间主任、办公室主任、厂长助理、副厂长、厂长;1993年至2016年1月,担任杭州中美华东制药有限公司董事长、总经理;2016年2月至今,担任杭州中美华东制药有限公司董事长;1993年至2016年1月5日,担任公司董事长、总经理;2016年1月6日至2019年6月5日担任公司董事长。2019年6月6日起任公司名誉董事长。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_李阅东","group":"board","name":"李阅东","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"120.0万","stockAmount":"-","description":"李阅东,男,1972年出生,加拿大魁北克大学项目管理硕士。历任浙江医药供销公司、浙江英特药业有限公司业务员、科长、爱邦保健品公司总经理,杭州朱养心药业有限公司副总经理、总经理、杭州华东医药集团有限公司副总经理。2014年4月至今担任华东医药股份有限公司董事,2016年8月至今担任华东医药股份有限公司副总经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_牛战旗","group":"board","name":"牛战旗","title":"董事","isMale":true,"age":"53","degree":"博士","salary":"3.000万","stockAmount":"-","description":"牛战旗,男,1967年出生,药剂学博士研究生学历。历任承德市技术监督局技术研究员、河北制药集团研究所副所长、石药集团技术开发部经理、石药集团欧意药业医学部经理、石药集团恩必普药业副总经理、石药集团高级研发总监;2013年3月至2016年6月,任中国远大集团有限责任公司医药集团管理总部副总裁兼研发管理部总经理;2016年6月至2018年11月任中国远大集团有限责任公司医药集团管理总部执行总裁;2018年11月至今任中国远大集团有限责任公司医药集团管理总部总裁。2016年6月至今担任华东医药股份有限公司董事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_亢伟","group":"board","name":"亢伟","title":"董事","isMale":false,"age":"52","degree":"硕士","salary":"3.000万","stockAmount":"-","description":"亢伟,女,1968年出生,硕士研究生学历。历任中国远大集团财务管理本部贸易处经理、资金处经理、财务管理经理;黑龙江远大购物中心财务总监、副总经理;现任中国远大集团财务总裁。2016年12月至今担任华东医药股份有限公司董事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_金旭虎","group":"board","name":"金旭虎","title":"董事","isMale":true,"age":"57","degree":"本科","salary":"1.750万","stockAmount":"-","description":"金旭虎,男,1963年出生,大学本科学历。历任杭州华东医药集团有限公司董事长、总经理。2019年1月至今任杭州市国有资本投资运营有限公司党委书记、董事长兼杭州华东医药集团有限公司执行董事、经理,杭州制氧机集团有限公司执行董事、经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_朱亮","group":"board","name":"朱亮","title":"董事","isMale":true,"age":"43","degree":"本科","salary":"40.00万","stockAmount":"-","description":"朱亮,男,1977年出生,大学本科学历。历任杭州华东医药集团有限公司工会主管,杭州华东医药集团有限公司工会副主席,杭州华东医药集团有限公司、华东医药股份有限公司工会主席,2017年4月至今担任公司监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_杨俊","group":"board","name":"杨俊","title":"独立董事","isMale":false,"age":"48","degree":"本科","salary":"4.670万","stockAmount":"-","description":"杨俊,女,1972年出生,本科学历,加拿大国籍。历任加拿大安大略省自由基金组织财务总监、上海安越企业管理咨询公司首席知识官及讲师合伙人、读客文化股份有限公司首席财务官,2018年6月至今,任上海越乘信息科技有限公司创始合伙人、首席顾问。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_钟晓明","group":"board","name":"钟晓明","title":"独立董事","isMale":true,"age":"58","degree":"博士","salary":"8.000万","stockAmount":"-","description":"钟晓明,男,1962年出生,硕士研究生学历。1985年至今,就职于浙江中医药大学,任新药办副主任、教授、硕士生、博士生导师。2013年至今,浙江大学首席科学家。2016年1月至今担任华东医药股份有限公司独立董事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_杨岚","group":"board","name":"杨岚","title":"独立董事","isMale":false,"age":"51","degree":"硕士","salary":"8.000万","stockAmount":"-","description":"杨岚女士,女,1969年出生,中国国籍,无境外永久居留权,硕士研究生学历,注册会计师、注册税务师、注册评估师,现任深圳中天精装股份有限公司独立董事。杨女士于1990年7月至1994年7月任贵阳市审计局科员;1994年8月至2000年1月,杨女士担任珠海立信会计师事务所任合伙人;2000年1月至2007年5月,杨女士任上海立信长江会计师事务所珠海分所副所长;2007年6月至2010年8月,杨女士任广东立信长江会计师事务所有限公司所长;2010年8月至2014年12月,杨女士任天健会计师事务所(特殊普通合伙)广东分所高级经理;2015年1月至2016年3月,杨女士担任广州证券创新投资管理有限公司财务总监;2016年3月至今,杨女士担任广州荣邦信息技术有限公司董事兼总经理。杨女士自2013年11月至今担任深圳中天精装股份有限公司独立董事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_白新华","group":"supervisoryCommittee","name":"白新华","title":"监事会主席","isMale":false,"age":"54","degree":"硕士","salary":"3.000万","stockAmount":"-","description":"白新华,女,1966年出生,硕士研究生学历。历任北京市审计局助理审计师,中国远大集团财务管理本部会计经理、监审部审计经理,现任中国远大集团财务管理总部副总经理。2003年至今担任华东医药股份有限公司监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_刘程炜","group":"supervisoryCommittee","name":"刘程炜","title":"监事","isMale":true,"age":"47","degree":"硕士","salary":"3.000万","stockAmount":"-","description":"刘程炜,男,1973年出生,硕士研究生学历。历任通用电气医疗系统中国公司金融服务经理、财务总监,通用电气医疗公司亚洲区心电监护财务经理。2001年加入中国远大集团,历任监审总监、投资经营总部副总经理,医药事业部副总经理、总经理、中国远大集团人寿健康保险公司筹备组组长。2016年8月至2018年9月担任远大医药(中国)有限公司副总经理。2018年9月至今任中国远大集团助理总裁。2003年至2016年1月担任华东医药股份有限公司董事;2016年1月至今任华东医药股份有限公司监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_秦云","group":"supervisoryCommittee","name":"秦云","title":"监事","isMale":false,"age":"50","degree":"本科","salary":"3.000万","stockAmount":"-","description":"秦云,女,1970年出生,大学本科学历。曾任北京首钢总医院内科主治医师、天津武田药品有限公司北京办事处医药代表、美国礼来亚洲公司北京办事处高级医药代表、中国医药外贸总公司销售分公司产品部主管;2002年就职于中国远大集团。历任医药事业部项目经理。现任中国远大集团医药集团管理总部运营部业务总监。2006年至今担任公司监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_胡宝珍","group":"supervisoryCommittee","name":"胡宝珍","title":"监事","isMale":false,"age":"47","degree":"本科","salary":"1.750万","stockAmount":"-","description":"胡宝珍,女,1973年3月出生,汉族,中共党员,大学本科学历,注册会计师、注册税务师、高级会计师。1997年7月起曾任浙江新亚实业有限公司助理会计、主办会计、财务部经理、总经理助理兼财务部经理;2009年3月至2019年3月任杭州市国资委财务总监、外派专职监事;现任杭州市国有资本投资运营有限公司风控法务部副部长、华东医药股份有限公司监事、杭州制氧机集团有限公司监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_何汝奋","group":"supervisoryCommittee","name":"何汝奋","title":"职工监事","isMale":false,"age":"52","degree":"本科","salary":"70.00万","stockAmount":"3.366万","description":"何汝奋,女,1968年出生,本科学历,高级会计师。1990年7月-1998年3月,历任杭州中美华东制药有限公司财务部经理助理;1998年4月-1998年12月,任公司财务部经理;1999年1月至2010年6月,任公司财务负责人;2010年7月至今,任公司商业副总经理。2019年6月6日起,担任华东医药股份有限公司职工监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_徐志锋","group":"supervisoryCommittee","name":"徐志锋","title":"职工监事","isMale":true,"age":"45","degree":"本科","salary":"40.00万","stockAmount":"-","description":"徐志锋,男,1975年出生,本科学历,经济师。1997年8月至2011年7月,历任杭州中美华东制药有限公司企管办专员、总经办主任助理;2011年8月2018年1月,任公司风险管理与审计部经理;2018年2月至今,任公司风险管理与审计部总监。2019年6月6日起,担任华东医药股份有限公司职工监事。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_李阅东","group":"manager","name":"李阅东","title":"总经理","isMale":true,"age":"48","degree":"硕士","salary":"120.0万","stockAmount":"-","description":"李阅东,男,1972年出生,加拿大魁北克大学项目管理硕士。历任浙江医药供销公司、浙江英特药业有限公司业务员、科长、爱邦保健品公司总经理,杭州朱养心药业有限公司副总经理、总经理、杭州华东医药集团有限公司副总经理。2014年4月至今担任华东医药股份有限公司董事,2016年8月至今担任华东医药股份有限公司副总经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_陈波","group":"manager","name":"陈波","title":"董事会秘书","isMale":true,"age":"48","degree":"硕士","salary":"80.00万","stockAmount":"-","description":"陈波,男,1972年出生,硕士研究生学历,经济师。2002年加入公司,华东医药股份有限公司融资部投资专员,融资部副经理,从2009年6月至今任华东医药股份有限公司董事会秘书,兼任投融资部经理、证券办主任。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_周顺华","group":"manager","name":"周顺华","title":"副总经理","isMale":true,"age":"60","degree":"硕士","salary":"130.0万","stockAmount":"-","description":"周顺华,男,1960年出生,硕士,经济师。1978年12月任职于公司,华东医药股份有限公司宣传干事、经营部经理、上海办事处主任、上海大区经理、杭州中美华东制药有限公司副总经理;2009年至今,担任华东医药股份有限公司副总经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_吴晖","group":"manager","name":"吴晖","title":"副总经理","isMale":true,"age":"51","degree":"硕士","salary":"80.00万","stockAmount":"-","description":"吴晖,男,1969年4月出生,硕士学历,教授级高工1991年7月任职于公司,历任杭州中美华东制药有限公司技术员、车间主任、总工程师;2015年至今,担任杭州中美华东制药有限公司副总经理;2019年6月6日起任公司副总经理。","lastUpdated":"2019-06-10"},{"id":"华东医药股份有限公司_邱仁波","group":"manager","name":"邱仁波","title":"财务负责人","isMale":true,"age":"38","degree":"硕士","salary":"70.00万","stockAmount":"-","description":"邱仁波,男,1982年出生,硕士研究生学历。(1)主要工作经历情况:2004年8月-2010年7月,历任华东医药股份有限公司财务管理本部专员、制造分公司财务科科长;2010年8月-2015年4月,任杭州中美华东制药有限公司财务部经理;2015年5月至今,任杭州中美华东制药有限公司财务总监。2019年12月起,任公司财务负责人。","lastUpdated":"2019-11-29"}],"companyName":"华东医药股份有限公司","province":"浙江省","englishName":"Huadong Medicine Co., Ltd.","industry":"医药生物 — 化学制药","website":"www.eastchinapharm.com","mainBusiness":"化学药、中药的原料药和制剂的生产销售,以及中西成药、中药材、医疗器械、健康产品等的经营","productsName":["中药肾病系列","糖尿病系列","免疫抑制剂系列","消化道系列","心脑血管系列"],"actualController":"胡凯军","actualControllerSharePercentage":"38.85%","registeredCapital":"17.5亿元","employeeAmount":"12118","phone":"86-0571-89903300","location":"浙江省杭州市拱墅区莫干山路866号","chineseDescription":"华东医药股份有限公司是一家医药生产及医药器械制造的企业。公司的主要产品主要为西药及中药药品、医药器械等。公司积极推进国际化进程，通过国际并购收购英国上市公司Sinclair100%股权，实现了医美销售网络全球布局；与美国R2、MediBeacon和瑞士Kylane等公司战略合作，增添国际商业化开发权益。加速产品国际注册，在线化学原料药全部获得美国FDA或欧盟等权威市场认证，注射用泮托拉唑钠冻干粉针获得美国FDA暂时批准，阿卡波糖片获得欧盟奥地利市场准入，均成为国内医药企业首家；在线全部原料药、部分制剂生产线获得美国FDA或欧盟等权威市场认证。","foundedDate":"1993-03-31","goPublicDate":"2000-01-27","companyHistory":"华东医药股份有限公司（以下简称本公司或公司）前身为杭州医药站股份有限公司，系于1993年3月成立的定向募集公司，于1993年3月31日在浙江省工商行政管理局登记注册，总部位于浙江省杭州市。公司现持有统一社会信用代码为91330000143083157E的营业执照，注册资本486,058,208.00元，股份总数486,058,208股（每股面值1元）。其中，有限售条件的流通股份：A股51,998,217股；无限售条件的流通股份A股434,059,991股。公司股票已于2000年1月27日在深圳证券交易所挂牌交易。\n　　截至2019年06月30日，有限售条件的流通股份：A股25,245股；无限售条件的流通股份：A股1,749,784,303股。收起▲","shareholders":[{"organizationId":"00009594","holderName":"中国远大集团有限责任公司","totalShare":"7.31亿","sharePercentage":"41.77%"},{"organizationId":"00005306","holderName":"杭州华东医药集团有限公司","totalShare":"2.88亿","sharePercentage":"16.46%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"3678.67万","sharePercentage":"2.10%"},{"organizationId":"","holderName":"全国社保基金一零六组合","totalShare":"2334.15万","sharePercentage":"1.33%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"2218.68万","sharePercentage":"1.27%"},{"organizationId":"","holderName":"泰康资产管理有限责任公司-积极配置投资产品","totalShare":"1855.43万","sharePercentage":"1.06%"},{"organizationId":"","holderName":"泰康人寿保险有限责任公司-分红-个人分红-019L-FH002深","totalShare":"1589.32万","sharePercentage":"0.91%"},{"organizationId":"","holderName":"国泰君安证券资管-光大银行-国泰君安君得明混合型集合资产管理计划","totalShare":"1319.99万","sharePercentage":"0.75%"},{"organizationId":"","holderName":"泰康人寿保险有限责任公司-投连-积极成长","totalShare":"986.67万","sharePercentage":"0.56%"},{"organizationId":"","holderName":"国泰君安证券资管-建设银行-国泰君安君得鑫股票集合资产管理计划","totalShare":"750.00万","sharePercentage":"0.43%"}],"englishDescription":"HUADONG MEDICINE CO., LTD is a China-based comprehensive pharmaceutical company. The Company is mainly engaged in the research and development of pharmaceuticals, the production and sales of chemical drugs, bulk drugs and preparations of traditional Chinese medicine, the distribution and retails of pharmaceuticals, medicine modern logistics, health industry, and the manufacturing and sales of medical beauty products. The Company's products principally include Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs and antibiotic drugs. The Company distributes its products in domestic market and to overseas markets.","englishIndustry":"Major Drugs","Price to earnings (ttm)":"15.93","Price to sales (ttm)":"1.42","Price to book (mrq)":"3.61","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"18.91","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"24.32","Return on equity (ttm)":"13.97","Income statement":{"Revenue":"35,445.70","Total revenue":"35,445.70","Cost of revenue, total":"24,083.00","Gross profit":"11,362.70","Selling/general/admin. expenses, total":"6,973.60","Research & development":"965.00","Depreciation/amortization":"237.37","Interest exp.(inc.),net-operating, total":"64.83","Unusual expense (income)":"(114.15)","Other operating expenses, total":"(160.98)","Total operating expense":"32,048.66","Operating income":"3,397.04","Gain (loss) on sale of assets":"(4.58)","Other, net":"77.80","Net income before taxes":"3,470.27","Provision for income taxes":"544.86","Net income after taxes":"2,925.40","Minority interest":"(112.28)","Net income before extra. items":"2,813.12","Net income":"2,813.12","Income available to com excl extraord":"2,813.12","Income available to com incl extraord":"2,813.12","Diluted net income":"2,813.12","Diluted weighted average shares":"1,749.81","Diluted eps excluding extraord items":"1.61","Dps - common stock primary issue":"0.28","Diluted normalized eps":"1.55"},"Balance sheet":{"Cash":"0.29","Cash & equivalents":"2,231.49","Cash and short term investments":"2,231.77","Accounts receivable - trade, net":"6,092.31","Total receivables, net":"6,928.14","Total inventory":"4,038.98","Prepaid expenses":"366.02","Other current assets, total":"170.96","Total current assets":"13,735.87","Property/plant/equipment, total - gross":"5,542.68","Accumulated depreciation, total":"(1,364.84)","Property/plant/equipment, total - net":"4,177.85","Goodwill, net":"1,469.62","Intangibles, net":"1,454.90","Long term investments":"485.97","Other long term assets, total":"139.77","Total assets":"21,463.97","Accounts payable":"3,789.05","Accrued expenses":"475.47","Notes payable/short term debt":"1,268.92","Other current liabilities, total":"2,863.19","Total current liabilities":"8,396.64","Long term debt":"0.00","Total long term debt":"0.00","Total debt":"1,268.92","Deferred income tax":"39.60","Minority interest":"557.15","Other liabilities, total":"161.11","Total liabilities":"9,154.50","Common stock, total":"1,749.81","Additional paid-in capital":"2,158.08","Retained earnings (accumulated deficit)":"8,378.79","Other equity, total":"22.79","Total equity":"12,309.48","Total liabilities & shareholders' equity":"21,463.97","Total common shares outstanding":"1,749.81","Tangible book value per share, common eq":"5.36","Current port. of  lt debt/capital leases":"28.47"},"Cash flow":{"Cash receipts":"37,765.48","Cash payments":"(26,049.85)","Cash taxes paid":"(2,115.42)","Changes in working capital":"(7,598.51)","Cash from operating activities":"2,001.70","Capital expenditures":"(1,353.44)","Other investing cash flow items, total":"(229.16)","Cash from investing activities":"(1,582.61)","Financing cash flow items":"(65.95)","Total cash dividends paid":"(570.63)","Issuance (retirement) of debt, net":"27.98","Cash from financing activities":"(608.60)","Foreign exchange effects":"22.57","Net change in cash":"(166.94)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"27.80","52 Week High":"32.55","52 Week Low":"16.02","Pricing date":"","10 Day Average Trading Volume":"35.71","Market Capitalization":"48,644.71","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"727.40","Beta":"0.73","1 Day Price Change":"0.00","13 Week Price Return (Daily)":"39.35","26 Week Price Return (Daily)":"33.33","5 Day Price Return (Daily)":"6.43","52 Week Price Return (Daily)":"3.27","Year To Date Price Return (Daily)":"14.03","Month to Date Price Return (Daily)":"9.88","Price Relative to S&P500 (4 Week)":"-0.22","Price Relative to S&P500 (13 Week)":"9.55","Price Relative to S&P500 (26 Week)":"4.43","Price Relative to S&P500 (52 Week)":"-29.82","Price Relative to S&P500 (YTD)":"-12.79"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.61","EPS excl. Extra Items (TTM)":"1.74","EPS Normalized (Annual)":"1.55","Revenue per Share (Annual)":"20.26","Revenue per Share (TTM)":"19.62","Book Value (Per Share Annual)":"7.03","Book Value (Per Share Quarterly)":"7.70","Tangible Book Value (Per Share Annual)":"5.36","Tangible Book Value (Per Share Quarterly)":"6.08","Cash Per Share (Per Share Annual)":"1.28","Cash Per Share (Per Share Quarterly)":"1.55","Cash Flow (Per Share Annual)":"1.90","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.28","Dividends (Per Share TTM)":"0.28","EBITD (Per Share TTM)":"1.87","EPS Basic excl. Extra Items (Annual)":"1.61","EPS Basic excl. Extra Items (TTM)":"1.74","EPS incl. Extra Items (Annual)":"1.61","EPS incl. Extra Items (TTM)":"1.74","Free Cash Flow (Per Share TTM)":"0.45","Dividend (Per Share 5Y)":"0.34"},"Valuation":{"P/E excl. Extra Items (Annual)":"17.29","P/E excl. Extra Items (TTM)":"15.93","P/E Normalized (Annual)":"17.88","Price to sales (Annual)":"1.37","Price to sales (TTM)":"1.42","Price to Tangible Book (Annual)":"5.18","Price to Tangible Book (Quarterly)":"4.57","Price to Free Cash Flow (Per Share Annual)":"626.65","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"61.34","Price to Book (Annual)":"3.95","Price to Book (Quarterly)":"3.61","P/E Basic excl. Extra Items (TTM)":"10.00","P/E excl. Extra Items High (TTM)":"34.63","P/E excl. Extra Items Low (TTM)":"10.00","P/E incl. Extra Items (TTM)":"15.93","Net Debt (Interim)":"-156.48","Net Debt (Annual)":"-962.85","Dividend Yield (5Y)":"1.41","Dividend Yield":"1.01","Current Dividend Yield (TTM)":"1.01"},"Financial Strength":{"Free Cash Flow (Annual)":"77.63","Current Ratio (Annual)":"1.64","Net Interest coverage (Annual)":"51.64","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"17.42","Quick Ratio (Annual)":"1.15","Total Debt/Total Equity (Annual)":"10.31","Current EV/Free Cash Flow (Annual)":"34.35","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.67","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"1.24","Total Debt/Total Equity (Quarterly)":"18.91","Free Cash Flow (TTM)":"793.00","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"16.05"},"Margins":{"Gross Margin (Annual)":"32.06","Gross Margin (TTM)":"32.93","Net Profit Margin % (Annual)":"8.25","Net Profit Margin (TTM)":"9.15","Operating Margin (Annual)":"9.58","Operating Margin (TTM)":"10.57","Pretax Margin (TTM)":"10.77","Pretax Margin (Annual)":"9.79","Operating Margin (5Y)":"8.43","Pretax Margin (5Y)":"8.49","Free Operating Cash Flow/Revenue (5Y)":"0.61","Free Operating Cash Flow/Revenue (TTM)":"2.31","Gross Margin (5Y)":"27.57","Net Profit Margin (5Y)":"7.02"},"Management Effectiveness":{"Return on Assets (Annual)":"14.38","Return on Equity (TTM)":"13.97","Return on Average Equity (Annual)":"25.29","Return on Average equity (TTM)":"25.14","Return on Investment (Annual)":"24.54","Return on Investment (TTM)":"24.32","Return on Average Assets (5Y)":"12.97","Return on Average Equity (5Y)":"26.22","Return on Investment (5Y)":"24.20","Asset Turnover (Annual)":"1.74","Asset Turnover (TTM)":"1.53","Inventory Turnover (Annual)":"6.09","Inventory Turnover (TTM)":"6.22","Net Income/Employee (Annual)":"253,699.00","Net Income/Employee (TTM)":"259,201.90","Receivables Turnover (Annual)":"6.05","Receivables Turnover (TTM)":"4.61","Revenue/Employee (Annual)":"3,073,948.00","Revenue/Employee (TTM)":"2,833,687.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"-11.41","Revenue Growth Rate (5Y)":"13.35","EPS Growth (Quarterly YoY)":"26.46","EPS Growth (TTM YoY)":"21.39","EPS Growth Rate (5Y)":"27.12","Dividend Growth Rate (3Y)":"-9.28","Revenue Growth (TTM YoY)":"5.55","Revenue Growth (Per Share 5Y)":"10.81","Revenue Growth Rate (3Y)":"11.78","EPS Growth Rate (3Y)":"24.49","Book Value Growth Rate (Per Share 5Y)":"37.13","Tangible Book Value Total Equity CAGR (5Y)":"36.74","Capital Spending growth rate 5 year":"33.03","EBITDA CAGR (5Y)":"21.34","EBITDA Interim CAGR (5Y)":"18.54","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"-12.89","Net Profit Margin Growth Rate (5Y)":"10.65"},"Income Statement":{"Revenue (Annual)":"35,445.70","Revenue (TTM)":"34,338.62","EBITD (Annual)":"3,750.65","EBITD (TTM)":"3,274.80","Earnings Before Taxes (Annual)":"3,470.27","Earnings Before Taxes (TTM)":"3,698.45","Net Income to Common (Annual)":"2,813.12","Net Income to Common (TTM)":"3,053.15","Earnings Before Taxes Normalized (Annual)":"3,360.69","Net Income Available to Common Normalized (Annual)":"2,720.75","Diluted Normalized EPS excl. Extra Items (TTM)":"1.57"}}}